haloperidol has been researched along with Depression in 124 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 9.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| " Clozapine significantly blunted ketamine-induced positive symptoms in patients with schizophrenia but not in healthy participants." | 9.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 9.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| " Higher levels of depression, hypersomnia, and leaden paralysis were noted in the patients who received haloperidol than in those who received phenelzine and those who received placebo." | 9.07 | Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. ( Cornelius, JR; Perel, JM; Soloff, PH; Ulrich, RF, 1993) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 9.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "We thus propose the l-methionine treatment as an animal model recapitulating several symptoms of schizophrenia." | 7.81 | A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity. ( Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z, 2015) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 7.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 7.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor." | 6.70 | Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. ( Berk, M; Schutz, G, 2001) |
| "The treatment with haloperidol worsened the adverse effects of chronic social stress having effects similar to stress on reward and motivation-related behaviours." | 5.35 | Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. ( Abumaria, N; Flügge, G; Fuchs, E; Havemann-Reinecke, U; Hiemke, C; Rüther, E; Rygula, R; Zernig, G, 2008) |
| "Physically aggressive inpatients with schizophrenia who received an evaluation of depression and impulsivity at baseline were randomly assigned in a double-blind, parallel group, 12-week trial to clozapine, olanzapine, or haloperidol." | 5.19 | Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. ( Czobor, P; Krakowski, MI, 2014) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 5.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| " Clozapine significantly blunted ketamine-induced positive symptoms in patients with schizophrenia but not in healthy participants." | 5.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| " In this post hoc analysis of the Brief Psychiatric Rating Scale anxiety-depression cluster, olanzapine therapy was associated with a significantly greater baseline-to-end-point improvement in the cluster compared with haloperidol therapy among 1996 randomized, double-blind subjects." | 5.09 | Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? ( Sanger, TM; Tollefson, GD, 1999) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 5.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| " Higher levels of depression, hypersomnia, and leaden paralysis were noted in the patients who received haloperidol than in those who received phenelzine and those who received placebo." | 5.07 | Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. ( Cornelius, JR; Perel, JM; Soloff, PH; Ulrich, RF, 1993) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 5.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| "To establish the differential indication of trazodone and to find the predictors of its efficacy, we conducted a study in which 45 patients with major depressive disorder and 75 patients with acute schizophrenia were randomly assigned under double-blind conditions to either 400 mg trazodone daily, 150 mg amitriptyline daily, 20 mg haloperidol daily, or placebo daily." | 5.06 | Experimental examination of trazodone. ( Klieser, E; Lehmann, E, 1989) |
| "Treatment of acute mania with second-generation antipsychotics has been claimed to involve a lower risk of switch to depression than haloperidol." | 4.89 | Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "The World Health Organization recommends that anxiety, depression, agitation and delirium at end of life should be treated with drugs such as lorazepam, diazepam, midazolam and haloperidol." | 3.83 | Look again at psychedelic drugs. ( Cameron, R, 2016) |
| "We thus propose the l-methionine treatment as an animal model recapitulating several symptoms of schizophrenia." | 3.81 | A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity. ( Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z, 2015) |
| " TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation." | 3.79 | A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. ( Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG, 2013) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 3.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 3.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "Previous studies have shown effects of MIF-1 (prolyl-leucyl-glycinamide) and Tyr-MIF-1 (tyrosyl-prolyl-leucyl-glycinamide) in animal models of depression and also effects on dopaminergic function." | 3.67 | Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats. ( Kastin, AJ; Pulvirenti, L, 1988) |
| " The drug does not possess an antidepressant action proper but activates the aggressive-defensive behaviour in experimental reserpine depression and reduces the provocation-induced aggressive behaviour in experimental haloperidol depression." | 3.66 | [Psychopharmacologic spectrum of melanostatin]. ( Klusha, VE; Kozlovskaia, MM; Svirskis, ShV; Val'dman, AV, 1980) |
| " This diabetes insipidus is reversible, non-progressive, unrelated to plasma level, and distinct in attack from lithium-induced hypothyroidism, which may occur at low dosage but is also usually of late onset and reversible or treatable with thyroxine while lithium is continued." | 3.65 | Blood levels and management of lithium treatment. ( Crammer, JL; Crane, G; Rosser, RM, 1974) |
| "Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol." | 2.77 | Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor." | 2.70 | Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. ( Berk, M; Schutz, G, 2001) |
| "Fluperlapine (NB-106-689) was tested on 26 schizophrenic patients in an open and crossover study." | 2.66 | Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. ( Bartels, M; Gärtner, HJ; Heimann, H; Mann, K; Schied, HW; Wagner, W, 1987) |
| " There appeared to be no difference between the viloxazine-treated group and the placebo-treated group, although the study raised some question as to the adequacies of the dosage utilized since there was an absence of any apparent side effects." | 2.65 | Viloxazine and the depressed schizophrenic--methodological issues. ( Kurland, AA; Nagaraju, A, 1981) |
| "Six patients with a family history of Huntington's chorea (HC) participated in a double blind crossover trial involving four treatments--lithium carbonate, haloperidol, lithium carbonate and haloperidol, and placebo." | 2.64 | A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. ( Brown, JG; Kidson, MA; Leonard, DP; Shannon, PJ; Taryan, S, 1975) |
| "Sertindole is a novel antipsychotic which has been tested in large clinical trials in North America and Europe; the results showed that this drug has efficacy against both the positive and negative symptoms of schizophrenia, while causing adverse neurological events at a similar level to that observed in patients taking placebo." | 2.40 | Sertindole: a review of clinical efficacy. ( Kane, JM, 1998) |
| "Depression is a prevalent psychiatric disorder with an increasing impact in global public health." | 1.46 | The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression. ( Alves, ND; Bessa, JM; Correia, JS; Machado-Santos, AR; Mateus-Pinheiro, A; Morais, M; Patrício, P; Pereira, J; Pinto, L; Sousa, N, 2017) |
| "The treatment with haloperidol worsened the adverse effects of chronic social stress having effects similar to stress on reward and motivation-related behaviours." | 1.35 | Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. ( Abumaria, N; Flügge, G; Fuchs, E; Havemann-Reinecke, U; Hiemke, C; Rüther, E; Rygula, R; Zernig, G, 2008) |
| "Depression in cancer patients is common and occurs throughout the course of cancer illness." | 1.31 | [Management of psychiatric symptoms in cancer patients]. ( Uchitomi, Y, 2002) |
| "Elderly women with depression are at risk even on a low dosis." | 1.29 | [Tardive dyskinesia: an increased risk of neuroleptics in elderly women]. ( Jessurun, AY; Stek, ML, 1995) |
| "Citalopram was inactive when given alone but it potentiated the antidepressant-like effect of MK-801." | 1.28 | Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. ( Maj, J; Rogóz, Z; Skuza, G; Sowińska, H, 1992) |
| "Pharmacotherapy of schizophrenia is a complex matter." | 1.28 | [Drug treatment of schizophrenic patients]. ( Finzen, A, 1991) |
| " After a diagnosis of "dysmorphic syndrome," haloperidol was prescribed at a dosage of 1 mg twice daily." | 1.27 | The dysmorphic syndrome. ( Koblenzer, CS, 1985) |
| "The counterbalanced design in a bioequivalent study of haloperidol indicated an absence of any clinical difference between a new 20-mg dosage form and two 10-mg tablets of haloperidol (Haldol)." | 1.26 | The dopamine radioreceptor assay--a clinical application. ( Hanlon, TE; Kurland, AA; Nagaraju, A, 1980) |
| "The TSH response in the groups with reactive depression, reactive paranoid psychosis, and neurotic depression, respectively, did not differ significantly from that found in controls." | 1.26 | Thyrotrophin-releasing hormone (TRH) stimulation test in manic-depressive illness. ( Bjørum, N; Cohn, D; Kirkegaard, C; Lauridsen, UB, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 69 (55.65) | 18.7374 |
| 1990's | 15 (12.10) | 18.2507 |
| 2000's | 17 (13.71) | 29.6817 |
| 2010's | 20 (16.13) | 24.3611 |
| 2020's | 3 (2.42) | 2.80 |
| Authors | Studies |
|---|---|
| Jaen, JC | 1 |
| Wise, LD | 1 |
| Heffner, TG | 1 |
| Pugsley, TA | 1 |
| Meltzer, LT | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Czopek, A | 1 |
| Bucki, A | 1 |
| Kołaczkowski, M | 1 |
| Zagórska, A | 1 |
| Drop, M | 1 |
| Pawłowski, M | 1 |
| Siwek, A | 1 |
| Głuch-Lutwin, M | 1 |
| Pękala, E | 1 |
| Chrzanowska, A | 1 |
| Struga, M | 1 |
| Partyka, A | 1 |
| Wesołowska, A | 1 |
| Léa Blondelle, KD | 1 |
| Simplice, FH | 1 |
| Hervé Hervé, NA | 1 |
| Eglantine, KW | 1 |
| Roland, RN | 1 |
| Jorelle Linda, DK | 1 |
| Balbine, KN | 1 |
| Simon Désiré, GN | 1 |
| Guillaume, CW | 1 |
| Alin, C | 1 |
| Kiselev, AV | 1 |
| Vedenkin, AS | 1 |
| Stovbun, IS | 1 |
| Sergienko, VI | 1 |
| Kalinina, TS | 1 |
| Veraart, JKE | 1 |
| Smith-Apeldoorn, SY | 1 |
| Bakker, IM | 1 |
| Visser, BAE | 1 |
| Kamphuis, J | 1 |
| Schoevers, RA | 1 |
| Touw, DJ | 1 |
| Morais, M | 1 |
| Patrício, P | 1 |
| Mateus-Pinheiro, A | 1 |
| Alves, ND | 1 |
| Machado-Santos, AR | 1 |
| Correia, JS | 1 |
| Pereira, J | 1 |
| Pinto, L | 1 |
| Sousa, N | 1 |
| Bessa, JM | 1 |
| Chajka, AV | 1 |
| Khusainov, DR | 1 |
| Cheretaev, IV | 1 |
| Koreniuk, II | 1 |
| Nozdracev, AD | 1 |
| Mavridis, D | 1 |
| White, IR | 1 |
| Krakowski, MI | 1 |
| Czobor, P | 2 |
| Esumi, S | 1 |
| Kawaski, Y | 1 |
| Nakamoto, A | 1 |
| Sagara, H | 1 |
| Gomita, Y | 1 |
| Kitamura, Y | 1 |
| Sendo, T | 1 |
| Cheĭdo, MA | 1 |
| Idova, GV | 1 |
| Wang, L | 1 |
| Alachkar, A | 1 |
| Sanathara, N | 1 |
| Belluzzi, JD | 1 |
| Wang, Z | 1 |
| Civelli, O | 1 |
| Potanin, SS | 1 |
| Burminskiy, DS | 1 |
| Morozova, MA | 1 |
| Platova, AI | 1 |
| Baymeeva, NV | 1 |
| Miroshnichenko, II | 1 |
| Chen, C | 1 |
| Nakagawa, S | 1 |
| Kitaichi, Y | 1 |
| An, Y | 1 |
| Omiya, Y | 1 |
| Song, N | 1 |
| Koga, M | 1 |
| Kato, A | 1 |
| Inoue, T | 1 |
| Kusumi, I | 1 |
| Cameron, R | 1 |
| Stone, EA | 1 |
| Lin, Y | 1 |
| Quartermain, D | 1 |
| Zhu, WL | 1 |
| Shi, HS | 1 |
| Wang, SJ | 1 |
| Wu, P | 1 |
| Ding, ZB | 1 |
| Lu, L | 1 |
| Riedel, M | 2 |
| Mayr, A | 2 |
| Seemüller, F | 2 |
| Maier, W | 2 |
| Klingberg, S | 1 |
| Heuser, I | 2 |
| Klosterkötter, J | 2 |
| Gastpar, M | 2 |
| Schmitt, A | 2 |
| Sauer, H | 1 |
| Schneider, F | 2 |
| Gaebel, W | 2 |
| Jäger, M | 2 |
| Möller, HJ | 3 |
| Schennach-Wolff, R | 1 |
| Collins, LE | 1 |
| Sager, TN | 1 |
| Sams, AG | 1 |
| Pennarola, A | 1 |
| Port, RG | 1 |
| Shahriari, M | 1 |
| Salamone, JD | 1 |
| Villarinho, JG | 1 |
| Fachinetto, R | 1 |
| de Vargas Pinheiro, F | 1 |
| da Silva Sant'Anna, G | 1 |
| Machado, P | 1 |
| Dombrowski, PA | 1 |
| da Cunha, C | 1 |
| de Almeida Cabrini, D | 1 |
| Pinto Martins, MA | 1 |
| Gauze Bonacorso, H | 1 |
| Zanatta, N | 1 |
| Antonello Rubin, M | 1 |
| Ferreira, J | 1 |
| Joshi, M | 1 |
| Akhtar, M | 1 |
| Najmi, AK | 1 |
| Khuroo, AH | 1 |
| Goswami, D | 1 |
| Revel, FG | 1 |
| Moreau, JL | 1 |
| Pouzet, B | 1 |
| Mory, R | 1 |
| Bradaia, A | 1 |
| Buchy, D | 1 |
| Metzler, V | 1 |
| Chaboz, S | 1 |
| Groebke Zbinden, K | 1 |
| Galley, G | 1 |
| Norcross, RD | 1 |
| Tuerck, D | 1 |
| Bruns, A | 1 |
| Morairty, SR | 1 |
| Kilduff, TS | 1 |
| Wallace, TL | 1 |
| Risterucci, C | 1 |
| Wettstein, JG | 1 |
| Hoener, MC | 1 |
| Schennach, R | 1 |
| Musil, R | 1 |
| Klingenberg, S | 1 |
| Schlösser, R | 1 |
| Ohmann, C | 1 |
| Lewitzka, U | 1 |
| Goikolea, JM | 1 |
| Colom, F | 1 |
| Torres, I | 1 |
| Capapey, J | 1 |
| Valentí, M | 1 |
| Undurraga, J | 1 |
| Grande, I | 1 |
| Sanchez-Moreno, J | 1 |
| Vieta, E | 1 |
| Peuskens, J | 1 |
| Puech, A | 1 |
| Chintawar, SD | 1 |
| Somani, RS | 1 |
| Kasture, VS | 1 |
| Kasture, SB | 1 |
| Uchitomi, Y | 1 |
| Oosthuizen, P | 1 |
| Emsley, RA | 1 |
| Roberts, MC | 1 |
| Turner, J | 1 |
| Keyter, L | 1 |
| Keyter, N | 1 |
| Torreman, M | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| LEHMANN, HE | 1 |
| BAN, TA | 1 |
| ROTH, M | 1 |
| VOLMAT, R | 1 |
| BEAUDOUIN, JL | 1 |
| COLLIN, J | 1 |
| NICOLAS-CHARLES, PJ | 1 |
| ALLERS, G | 1 |
| SCHWARZ, H | 1 |
| KRUEGER, HJ | 1 |
| JUENEMANN, HJ | 1 |
| Gerle, B | 2 |
| KAMENSKAIA, VM | 1 |
| ALEKSANDROVSKII, IuA | 1 |
| WEIDTMANN, W | 1 |
| RUGGERINI, R | 1 |
| ZECCA, C | 1 |
| El Yacoubi, M | 1 |
| Costentin, J | 2 |
| Vaugeois, JM | 2 |
| Capasso, R | 1 |
| Borrelli, F | 1 |
| Capasso, F | 1 |
| Mascolo, N | 1 |
| Izzo, AA | 1 |
| Rosenheck, RA | 1 |
| Katzav, A | 1 |
| Solodeev, I | 1 |
| Brodsky, O | 1 |
| Chapman, J | 1 |
| Pick, CG | 1 |
| Blank, M | 1 |
| Zhang, W | 1 |
| Reichlin, M | 1 |
| Shoenfeld, Y | 1 |
| Dávila, R | 1 |
| Zumárraga, M | 1 |
| Basterreche, N | 1 |
| Arrúe, A | 1 |
| Anguiano, JB | 1 |
| Rygula, R | 1 |
| Abumaria, N | 1 |
| Havemann-Reinecke, U | 1 |
| Rüther, E | 2 |
| Hiemke, C | 1 |
| Zernig, G | 1 |
| Fuchs, E | 1 |
| Flügge, G | 1 |
| Val'dman, AV | 1 |
| Kozlovskaia, MM | 1 |
| Klusha, VE | 1 |
| Svirskis, ShV | 1 |
| Kurland, AA | 2 |
| Nagaraju, A | 2 |
| Hanlon, TE | 1 |
| Montanaro, N | 1 |
| Dall'Olio, R | 1 |
| Gandolfi, O | 1 |
| Vaccheri, A | 1 |
| Bruun, RD | 1 |
| Deveaugh-Geiss, J | 1 |
| Pandurangi, A | 1 |
| Weinstein, F | 1 |
| Minter, RE | 1 |
| Verdugo, N | 1 |
| Mandel, MR | 1 |
| Nordbø, K | 1 |
| Cornelius, JR | 1 |
| Soloff, PH | 1 |
| Perel, JM | 1 |
| Ulrich, RF | 1 |
| Pouhé, D | 1 |
| Zuccaro, F | 1 |
| Jessurun, AY | 1 |
| Stek, ML | 1 |
| Lynch, G | 1 |
| Green, JF | 1 |
| King, DJ | 1 |
| Suzuki, E | 1 |
| Kanba, S | 1 |
| Koshikawa, H | 1 |
| Nibuya, M | 1 |
| Yagi, G | 1 |
| Asai, M | 1 |
| Krakowski, M | 1 |
| Volavka, J | 1 |
| Gil, M | 1 |
| Armario, A | 1 |
| Tollefson, GD | 2 |
| Sanger, TM | 2 |
| Beasley, CM | 1 |
| Tran, PV | 1 |
| Kane, JM | 1 |
| Thiam, MH | 1 |
| Gueye, EM | 1 |
| Badiane, SB | 1 |
| Kourouma, BK | 1 |
| Sylla, A | 1 |
| Sylla, O | 1 |
| Gueye, M | 1 |
| Yao, JK | 1 |
| Reddy, R | 1 |
| van Kammen, DP | 1 |
| Shad, MU | 1 |
| Marsh, C | 1 |
| Preskorn, SH | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Suzuki, A | 1 |
| Kondo, T | 1 |
| Mihara, K | 1 |
| Yasui-Furukori, N | 1 |
| Ishida, M | 1 |
| Furukori, H | 1 |
| Kaneko, S | 1 |
| Inoue, Y | 1 |
| Otani, K | 1 |
| Schutz, G | 1 |
| Berk, M | 1 |
| Sim, M | 1 |
| Nelson, JC | 1 |
| Bowers, MB | 1 |
| Heath, A | 1 |
| Singh, MM | 1 |
| Kay, SR | 1 |
| Kirkegaard, C | 1 |
| Bjørum, N | 1 |
| Cohn, D | 1 |
| Lauridsen, UB | 1 |
| Leonard, DP | 1 |
| Kidson, MA | 1 |
| Brown, JG | 1 |
| Shannon, PJ | 1 |
| Taryan, S | 1 |
| Ballenger, JC | 1 |
| Post, RM | 1 |
| Alkhimova, LN | 1 |
| Ashford, JW | 1 |
| Ford, CV | 1 |
| Kalman, T | 1 |
| Warner, GM | 1 |
| Markianos, ES | 1 |
| Nyström, I | 1 |
| Reichel, H | 1 |
| Matussek, N | 1 |
| König, L | 1 |
| Lange, E | 1 |
| Robak, OH | 1 |
| Schilkrut, R | 1 |
| Ackenheil, M | 1 |
| Eben, E | 1 |
| Hippius, H | 1 |
| Brion, S | 1 |
| Chevalier, JF | 1 |
| Guerin, R | 1 |
| Ginestet, D | 1 |
| Gomez, J | 1 |
| Dally, P | 1 |
| McLaren, S | 1 |
| Cookson, JC | 1 |
| Silverstone, T | 1 |
| Maj, J | 1 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Sowińska, H | 1 |
| Finzen, A | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Mann, K | 1 |
| Bartels, M | 1 |
| Gärtner, HJ | 1 |
| Schied, HW | 1 |
| Wagner, W | 1 |
| Heimann, H | 2 |
| Pulvirenti, L | 1 |
| Kastin, AJ | 1 |
| Lerner, Y | 1 |
| Mintzer, Y | 1 |
| Schestatzky, M | 1 |
| Koblenzer, CS | 1 |
| Hollister, LE | 1 |
| de Groot, MH | 1 |
| Davis, JM | 1 |
| Man, PL | 1 |
| Luckey, WT | 1 |
| Schiele, BC | 1 |
| Semanovskaia, EI | 1 |
| Crammer, JL | 1 |
| Rosser, RM | 1 |
| Crane, G | 1 |
| Gill, J | 1 |
| de L Horne, DJ | 1 |
| Angrist, B | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gershon, S | 3 |
| Shapiro, AK | 1 |
| Shapiro, E | 1 |
| Wayne, H | 1 |
| Goforth, EG | 1 |
| Schmocker, A | 1 |
| Shopsin, B | 1 |
| Cookson, IB | 1 |
| Wells, PG | 1 |
| Pitt, B | 1 |
| Kammerer, M | 1 |
| Wartel, R | 1 |
| Gurfein, L | 1 |
| Weil, J | 1 |
| Wysoki, V | 1 |
| Gelb, F | 1 |
| Cocito, E | 1 |
| Ambrosini, G | 1 |
| Arata, A | 1 |
| Bevilacqua, P | 1 |
| Tortora, E | 1 |
| Rogerson, R | 1 |
| Butler, JK | 1 |
| Ayd, FJ | 1 |
| Morgan, HG | 1 |
| Sanghvi, I | 1 |
| Urquiaga, X | 1 |
| Inose, T | 1 |
| Hirata, I | 1 |
| Kawajiwara, A | 1 |
| Iwata, T | 1 |
| Tano, T | 1 |
| Voelkel, A | 1 |
| Lichko, AE | 1 |
| Marchenko, BV | 1 |
| Prakhov, VI | 1 |
| Radavichius, LI | 1 |
| Khaliavin, AV | 1 |
| Oesterreich, K | 1 |
| Greger, J | 1 |
| Glitschka, A | 1 |
| Müller, K | 1 |
| Kojak, G | 1 |
| Barry, MJ | 1 |
| Gastineau, CF | 1 |
| Fiume, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures[NCT00409201] | Phase 1 | 30 participants | Interventional | 2006-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for haloperidol and Depression
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio | 2021 |
Dealing with missing outcome data in meta-analysis.
Topics: Bias; Data Collection; Data Interpretation, Statistical; Depression; Haloperidol; Humans; Meta-Analy | 2020 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disord | 2013 |
CLINICAL OBSERVATIONS OF THE SIDE-EFFECTS OF HALOPERIDOL.
Topics: Depression; Gastrointestinal Diseases; Haloperidol; Heart Diseases; Hematopoiesis; Humans; Hypotensi | 1964 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloper | 2005 |
Sertindole: a review of clinical efficacy.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Depression; Haloperidol; Humans; Imidazoles; Indoles | 1998 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
Psychiatric drug treatment in children.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child; | 1979 |
25 trials available for haloperidol and Depression
| Article | Year |
|---|---|
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Depression; Double-Blind Method | 2014 |
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Double-Blind Method; Female; Follow-Up St | 2012 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; | 2012 |
Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depression; Double-Blind Metho | 2002 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Viloxazine and the depressed schizophrenic--methodological issues.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Comb | 1981 |
Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.
Topics: Adult; Borderline Personality Disorder; Depression; Double-Blind Method; Drug Administration Schedul | 1993 |
Antipsychotic drug-induced dysphoria.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; H | 1996 |
Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Female; Haloperidol; Humans; Male; | 1997 |
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Dose-Response Relationship, Drug; | 1998 |
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Topics: Antipsychotic Agents; Anxiety; Benzodiazepines; Brief Psychiatric Rating Scale; Depression; Double-B | 1999 |
Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.
Topics: Adult; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Drug Therapy, Combin | 2001 |
A double blind trial of lithium carbonate and haloperidol in Huntington's chorea.
Topics: Anger; Carbonates; Clinical Trials as Topic; Depression; Depression, Chemical; Drug Therapy, Combina | 1975 |
Therapeutic effects of carbamazepine in affective illness: a preliminary report.
Topics: Adult; Affective Symptoms; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depression; Do | 1978 |
[Comparative analysis of haloperidol effect on depressive states in the early patients].
Topics: Adult; Age Factors; Aged; Clinical Trials as Topic; Depression; Female; Haloperidol; Humans; Male; M | 1978 |
Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
Topics: Adult; Aged; Chronic Disease; Depression; Double-Blind Method; Female; Fluphenazine; Haloperidol; Hu | 1992 |
Experimental examination of trazodone.
Topics: Adult; Amitriptyline; Anxiety; Depression; Depressive Disorder; Double-Blind Method; Female; Haloper | 1989 |
Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Dibenzazepines; F | 1987 |
Lithium combined with haloperidol in schizophrenic patients.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Combinat | 1988 |
A comparison of haloperidol and Trifluoperazine. (A double-blind, controlled study on chronic schizophrenic outpatients).
Topics: Clinical Trials as Topic; Depression; Extrapyramidal Tracts; Haloperidol; Humans; Male; Middle Aged; | 1967 |
[Assessment of the severity of psychiatric states].
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Drug Evaluation; Haloperidol; Humans; Interview | 1974 |
The current status of lithium in psychiatry.
Topics: Acute Disease; Bipolar Disorder; Chlorpromazine; Clinical Trials as Topic; Depression; Female; Halop | 1974 |
[Clinical experimentation with desipramine with statistical control].
Topics: Adult; Aged; Anorexia Nervosa; Barbiturates; Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Cli | 1968 |
Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol.
Topics: Adult; Asthenia; Benperidol; Catatonia; Clinical Trials as Topic; Depression; Haloperidol; Humans; H | 1970 |
Assessment of low dosage haloperidol in anxiety states.
Topics: Adult; Aged; Anxiety; Clinical Trials as Topic; Depression; Female; Haloperidol; Humans; Male; Middl | 1971 |
90 other studies available for haloperidol and Depression
| Article | Year |
|---|---|
Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones.
Topics: Animals; Antipsychotic Agents; Benzopyrans; Binding, Competitive; Brain; Corpus Striatum; Depression | 1991 |
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Receptors, Serotonin; St | 2019 |
Antidepressant, anti-amnesic and vasoprotective effect of Bombax costatum Pellegr. & Vuillet aqueous stem bark extract on chronic mild unpredictable stress induced in rat.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Bombax; Depression; Depressi | 2022 |
Calcium Salt of N-(5-Hydroxynicotinoyl)-L-Glutamic Acid Weakens Depressive-Like Behavior and Parkinsonian Syndrome in Experiment on Rodents.
Topics: Animals; Antidepressive Agents; Calcium; Catalepsy; Depression; Glutamic Acid; Haloperidol; Male; Mi | 2019 |
The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression.
Topics: Affect; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Cell Survival; Cloza | 2017 |
[CHRONIC D2-RECEPTOR BLOCKADE AND BEHAVIOR OF LOW DEPRESSIVE RATS].
Topics: Animals; Animals, Outbred Strains; Behavior, Animal; Depression; Dopamine D2 Receptor Antagonists; D | 2017 |
Differential effects of nomifensine and imipramine on motivated behavior in the runway model of intracranial self-stimulation.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Depression; Dopamine | 2013 |
[Effect of dopamine D1 and D2 receptor blockade on the immunostimulating effect of δ1 opioid receptor agonist DPDPE in mice with different psychoemotional states].
Topics: Aggression; Analgesics, Opioid; Animals; Benzazepines; Depression; Dopamine Antagonists; Enkephalin, | 2015 |
A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Depression; Disease Models, Animal; Ha | 2015 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapi | 2015 |
The role of medial prefrontal corticosterone and dopamine in the antidepressant-like effect of exercise.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Depressive Disorder; Dopamine; Glucocort | 2016 |
Look again at psychedelic drugs.
Topics: Anxiety; Delirium; Depression; Diazepam; Hallucinogens; Haloperidol; Humans; Lorazepam; Midazolam; P | 2016 |
Evaluation of the repeated open-space swim model of depression in the mouse.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Hippocampal CA3 calcineurin activity participates in depressive-like behavior in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bridged Bicyclo Compounds; CA3 Region, Hippocampal | 2011 |
The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Choice Behavior; Depression; Dopamine | 2012 |
Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Topics: Animals; Anisoles; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Depression; | 2012 |
Effect of zinc in animal models of anxiety, depression and psychosis.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Agents; Chlorides; Depression; Disease Mo | 2012 |
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocain | 2013 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M | 2002 |
Nootropic activity of Albizzia lebbeck in mice.
Topics: Albizzia; Animals; Avoidance Learning; Behavior, Animal; Brain Chemistry; Catalepsy; Clonidine; Depr | 2002 |
[Management of psychiatric symptoms in cancer patients].
Topics: Antidepressive Agents; Delirium; Depression; Disease Management; Dopamine Antagonists; Haloperidol; | 2002 |
NOTES FROM THE LOG-BOOK OF A PSYCHOPHARMACOLOGICAL RESEARCH UNIT I.
Topics: Amobarbital; Behavior; Books; Chlordiazepoxide; Depression; Dextroamphetamine; Electroconvulsive The | 1964 |
DEPRESSIVE AND MANIC PSYCHOSES AND ALLIED DISORDERS.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Barbiturates; Bipolar Disorder; Depression; Electr | 1964 |
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope | 1964 |
[CLINICO-THERAPEUTIC TRIALS WITH DIPIPERON, A NEW BUTYROPHENONE SERIES DERIVATIVE].
Topics: Butyrophenones; Depression; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psychoti | 1964 |
[CLINICO-ELECTROENCEPHALOGRAPHIC STUDY OF THE EFFECT OF HALOPERIDOL ON SCHIZOPHRENICS].
Topics: Catatonia; Depression; Depressive Disorder; Drug Therapy; Electroencephalography; Haloperidol; Human | 1964 |
[SOMATOTHERAPY OF ENDOGENOUS PSYCHOSES AT MARBURG UNIVERSITY NEUROLOGIC CLINIC].
Topics: Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Chlorprothixene; Convulsive Therapy; Depression; | 1964 |
[HALOPERIDOL IN PREMEDICATION FOR ELECTROSHOCK THERAPY].
Topics: Convulsive Therapy; Delusions; Depression; Depressive Disorder; Electricity; Electroconvulsive Thera | 1964 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caff | 2003 |
Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Topics: Acetylcholine; Adenosine Triphosphate; Animals; Anthracenes; Antidepressive Agents; Atropine; Bridge | 2004 |
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system.
Topics: Animals; Antibodies, Anti-Idiotypic; Antidepressive Agents, Second-Generation; Autoimmunity; Brain; | 2007 |
Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Depression; Dopamine; Female; Hallucinations; Haloperidol; | 2007 |
Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Depress | 2008 |
[Psychopharmacologic spectrum of melanostatin].
Topics: Aggression; Amantadine; Animals; Behavior, Animal; Biogenic Amines; Brain Chemistry; Catalepsy; Cats | 1980 |
The dopamine radioreceptor assay--a clinical application.
Topics: Adult; Aged; Antipsychotic Agents; Behavior; Corpus Striatum; Depression; Female; Haloperidol; Human | 1980 |
Neuroleptic versus antidepressant activity of sulpiride isomers in the rat.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Apomorphine; Behavior, Animal; Depression; Exp | 1982 |
Dysphoric phenomena associated with haloperidol treatment of Tourette syndrome.
Topics: Adult; Akathisia, Drug-Induced; Child; Depression; Female; Haloperidol; Humans; Male; Tourette Syndr | 1982 |
Confusional paranoid psychosis after withdrawal from sympathomimetic amines: two case reports.
Topics: Adult; Aged; Depression; Dextroamphetamine; Diethylpropion; Female; Haloperidol; Humans; Male; Obesi | 1982 |
Neuroleptic-induced depression?
Topics: Depression; Haloperidol; Humans | 1980 |
The treatment of delusional depression with tranylcypromine: a case report.
Topics: Delusions; Depression; Electroconvulsive Therapy; Female; Haloperidol; Humans; Middle Aged; Tranylcy | 1980 |
[Haloperidol-induced akathisia in the state of violence].
Topics: Depression; Haloperidol; Humans; Imipramine; Motor Activity; Violence | 1980 |
Indirect dopamine agonists effects on despair test: dissociation from hyperactivity.
Topics: Animals; Benzazepines; Depression; Dextroamphetamine; Dopamine Agonists; Dopamine Antagonists; Dopam | 1996 |
[Tardive dyskinesia: an increased risk of neuroleptics in elderly women].
Topics: Aged; Antipsychotic Agents; Depression; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans | 1995 |
Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Topics: Adult; Aged; Antipsychotic Agents; Depression; Dopamine D2 Receptor Antagonists; Dose-Response Relat | 1996 |
Chronic immobilization stress appears to increase the role of dopamine in the control of active behaviour in the forced swimming test.
Topics: Animals; Behavior, Animal; Depression; Dopamine; Dopamine Antagonists; Haloperidol; Immobilization; | 1998 |
[Apropos of 1 attempted suicide with a fire arm in an adolescent].
Topics: Adolescent; Antipsychotic Agents; Depression; Family; Haloperidol; Humans; Male; Suicide, Attempted | 1999 |
Abnormal age-related changes of plasma antioxidant proteins in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aging; Albumins; Antipsychotic Agents; Anxiety; Bilirubin; Depressio | 2000 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo | 2001 |
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzamides; Depression; Dopamine Antagonists; Female; Haloperi | 2001 |
Drugs for psychiatric disorders.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; | 1976 |
The treatment of severely depressed schizophrenic patients.
Topics: Acute Disease; Antipsychotic Agents; Delayed-Action Preparations; Depression; Electroconvulsive Ther | 1978 |
Delusional unipolar depression: description and drug response.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antipsychotic Agents; Delusions; Depression; Fema | 1978 |
Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
Topics: Adult; Antipsychotic Agents; Anxiety; Arousal; Autonomic Nervous System; Basal Ganglia Diseases; Chl | 1979 |
Thyrotrophin-releasing hormone (TRH) stimulation test in manic-depressive illness.
Topics: Adjustment Disorders; Adult; Age Factors; Aged; Biperiden; Bipolar Disorder; Depression; Female; Hal | 1978 |
Use of MAO inhibitors in elderly patients.
Topics: Aged; Depression; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 1979 |
Protracted vomiting following abrupt cessation of psychotropics: a case report.
Topics: Adult; Benztropine; Depression; Drug Therapy, Combination; Haloperidol; Humans; Imipramine; Male; Sc | 1978 |
Serum dopamine-beta-hydroxylase in psychiatric patients and normals. Effect of d-amphetamine and haloperidol.
Topics: Depression; Dextroamphetamine; Dopamine beta-Hydroxylase; Haloperidol; Humans; Mental Disorders; Sch | 1976 |
[Significance and advantages of Orap in the ambulatory care of schizophrenic psychoses].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Cyclothymic Disorder; Depression; Depressive Disorder, Maj | 1976 |
[Ambulatory treatment of psychoses. Report from a discussion meeting].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Depression; Haloperidol; Humans; Injections, I | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
[Chemotherapy of melancholia by sequential neuroleptic-viloxazine association].
Topics: Adjustment Disorders; Adult; Bipolar Disorder; Chlorpromazine; Depression; Depressive Disorder, Majo | 1976 |
Intravenous tranquillization with ECT.
Topics: Adjustment Disorders; Adult; Aged; Amnesia, Retrograde; Anxiety; Depression; Diazepam; Electroconvul | 1975 |
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Haloperidol; Imipramine | 1992 |
[Drug treatment of schizophrenic patients].
Topics: Antipsychotic Agents; Depression; Haloperidol; Humans; Patient Compliance; Psychotherapy; Schizophre | 1991 |
Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Haloperidol; Immobilization; Male; MSH | 1988 |
The dysmorphic syndrome.
Topics: Adolescent; Adult; Aged; Body Image; Delusions; Depression; Female; Haloperidol; Humans; Male; Middl | 1985 |
Clinical differences among phenothiazines in schizophrenics. Introduction: specific indications for antipsychotics: elusive end of the rainbow.
Topics: Antipsychotic Agents; Depression; Haloperidol; Humans; Kinetics; Perphenazine; Phenothiazines; Piper | 1974 |
The clinical use of psychotherapeutic drugs in the elderly.
Topics: Aged; Aging; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Benzodiazepi | 1974 |
Psychopharmacology in the aged. Use of psychotropic drugs in geriatric patients.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Depression; Dih | 1974 |
Long-term effects of haloperidol.
Topics: Adolescent; Adult; Back Pain; Basal Ganglia Diseases; Bipolar Disorder; Depression; Depressive Disor | 1973 |
[Affective disorders in the course of treatment with neuroleptics of children and adolescents with schizophrenia].
Topics: Adolescent; Affect; Child; Child, Preschool; Chlorpromazine; Depression; Haloperidol; Humans; Moveme | 1967 |
Blood levels and management of lithium treatment.
Topics: Administration, Oral; Adult; Aged; Carbimazole; Delayed-Action Preparations; Dementia; Depression; D | 1974 |
Psychological testing in depressive illness. I. Psychomotor performance.
Topics: Adult; Bipolar Disorder; Depression; Diagnosis, Differential; Female; Haloperidol; Humans; Male; Mid | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Treatment of Tourette's syndrome with haloperidol, review of 34 cases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Child; Depression; Evaluation Studies as Topic; Female; F | 1973 |
A single case study. Gilles de la Tourette's syndrome.
Topics: Adult; Depression; Female; Follow-Up Studies; Haloperidol; Histrionic Personality Disorder; Humans; | 1974 |
Letter: Haloperidol in the treatment of stutterers.
Topics: Depression; Ethanol; Haloperidol; Humans; Piperazines; Sleep; Stuttering; Substance Withdrawal Syndr | 1973 |
Letter: Withdrawal symptoms after stopping phenelzine?
Topics: Adult; Depression; Female; Haloperidol; Headache; Humans; Male; Phenelzine; Shivering; Substance Wit | 1974 |
Comparative trial of low dose haloperidol and fluphenazine in office patients.
Topics: Adult; Affect; Aged; Depression; Evaluation Studies as Topic; Female; Fluphenazine; Haloperidol; Hum | 1972 |
The incidence of depressive symptoms during recovery from hypomania.
Topics: Bipolar Disorder; Chlorpromazine; Convalescence; Depression; Follow-Up Studies; Haloperidol; Humans; | 1972 |
Exploration of the anti-depressant potential of L-dopa.
Topics: Animals; Antidepressive Agents; Behavior; Blood Pressure; Carboxy-Lyases; Depression; Dihydroxypheny | 1971 |
Haloperidol.
Topics: Depression; Haloperidol; Humans; Schizophrenia; Tourette Syndrome | 1967 |
[Depressive condition with electroencephalographic abnormalities--contribution to differential diagnosis of endogenous depression].
Topics: Adolescent; Adult; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Depression; Diagnosis, Di | 1969 |
[Complications caused by anonymous preclinical medication].
Topics: Amitriptyline; Antidepressive Agents; Barbiturates; Bromides; Cannabis; Chlordiazepoxide; Delirium; | 1970 |
[Features of a reaction to intravenous haloperidol administration].
Topics: Adult; Aggression; Alcoholism; Anxiety; Depression; Hallucinations; Haloperidol; Humans; Injections, | 1971 |
[On vital feelings and their treatment with the butyrophenone derivative haloperidol].
Topics: Adult; Aged; Depression; Female; Haloperidol; Humans; Male; Middle Aged; Psychophysiologic Disorders | 1967 |
[Clinical use of butyrophenones].
Topics: Butyrophenones; Chlorpromazine; Depression; Haloperidol; Humans; Hypnotics and Sedatives; Schizophre | 1968 |
[On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
Topics: Adult; Aged; Bipolar Disorder; Catatonia; Child; Depression; Depressive Disorder, Major; Extrapyrami | 1968 |
Severe hypoglycemic reaction with haloperidol: report of a case.
Topics: Aged; Delusions; Depression; Electroconvulsive Therapy; Female; Haloperidol; Humans; Hypoglycemia | 1969 |
[On the pharmacological effects of an association of haloperidol and isopropamide bromide].
Topics: Anxiety; Depression; Female; Haloperidol; Humans; Male; Neurasthenia; Neurotic Disorders; Parasympat | 1966 |